Inozyme Pharma Inc. (INZY)
NASDAQ: INZY
· Real-Time Price · USD
3.96
0.00 (0.13%)
At close: May 29, 2025, 3:59 PM
3.95
-0.12%
After-hours: May 29, 2025, 07:27 PM EDT
Company Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.
The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
It has a license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma Inc.
| Country | United States |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Dr. Douglas A. Treco Ph.D. |
Contact Details
Address: 321 Summer Street Boston, Massachusetts United States | |
| Website | https://www.inozyme.com |
Stock Details
| Ticker Symbol | INZY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001693011 |
| CUSIP Number | 45790W108 |
| ISIN Number | US45790W1080 |
| Employer ID | 47-5129768 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas A. Treco Ph.D. | Chief Executive Officer & Chairman |
| Dr. Matthew Winton Ph.D. | Senior Vice President & Chief Operating Officer |
| Gayle Gironda | Senior Vice President & Chief People Officer |
| Sanjay S. Subramanian M.B.A., M.S. | Chief Financial Officer, Head of Business Development, Principal Accounting Officer & Corporate Secretary |
| Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor & Director |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer |
| Dr. Yves Sabbagh Ph.D. | Senior Vice President, Chief Scientific Officer & Chair of the Scientific Advisory Board |
| Petra Duda M.D., Ph.D. | Chief Medical Officer |
| Stefan Riley | Director of Investor Relations |
| Stephen J. Di Palma M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | SCHEDULE 13G | Filing |
| May 20, 2025 | 4 | Filing |
| May 20, 2025 | SC14D9C | Filing |
| May 19, 2025 | SC TO-C | Filing |
| May 19, 2025 | SC TO-C | Filing |
| May 16, 2025 | SC TO-C | Filing |
| May 16, 2025 | SC14D9C | Filing |
| May 16, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |